A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety/tolerability of NB1011 infusions
United States: Food and Drug Administration
CR-TSC-001
NCT00248404
September 2005
Name | Location |
---|---|
University of Minnesota | Minneapolis, Minnesota 55455 |
USC Norris Comprehensive Cancer Center | Los Angeles, California 90089 |